ARRAY BIOPHARMA
| WVB Number : USA000032612 | Country : United States of America |
| SIC categorization : MEDICAL LABORATORIES (8071) | ISIN : US04269X1054 |
| FT categorization : HEALTH CARE (431) | |
| Company status: ACTIVE |
» Corporation Profile :
| Profile in brief: The Company is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat debilitating and life-threatening diseases. |
|
| Phone : 1 303 381 6600 | Fax : 303 386 1390 |
| Chairman: : KYLE LEFKOFF | Auditor : KPMG LLP |
| CEO/Managing Director : ROBERT E. CONWAY | |
» Company Facts
| Net Profit Margin (%) | -511.63 |
| Operating Margin (%) | -472.66 |
| Return on Assets (%) | -99.03 |
| Return on Equity (%) | 716.57 |
| Employees | 355 |
» Company Financials
| Annual (2009) | |
| Income Statement ('000 USD ) |
|
| Sales/Total Revenue | 24,982 |
| EBITDA | -95,840 |
| EBIT | -102,453 |
| Net Income | -127,815 |
| Balance Sheet ( '000 USD) |
|
| Total Current Assets | 44,917 |
| Total Assets | 95,055 |
| Current Liabilities | 50,295 |
| Total Liabilities & Debt | 168,756 |
| Total Equity | -73,701 |
| Cash & Flow ( '000 USD) |
|
| Net Income/Staring Line | -127,815 |
| Cash from Operating | -86,153 |
| Cash from Investing | 29,005 |
| Cash from Financing | 40,688 |
| Cash & Equivalent Yr End | 39,988 |